Table 2.
The mediation effect of glucosamine on cognition, and sarcopenia-related traits via BMR.
| Effect of glucosamine on cognition, and sarcopenia-related traits after adjusted by BMR | Effect of BMR on cognition, and sarcopenia-related traits | |||
|---|---|---|---|---|
| Outcomes | Effect estimate (IVW): OR (95% CI) |
p-value | Effect estimate (IVW): OR (95% CI) |
p-value |
| cognitive performance | 1.5 (1.04, 2.17) | 0.031 | 1.08 (1.04, 1.13) | 4.24E-05 |
| FIS | 2.3 (0.98, 5.41) | 0.057 | 1.23 (1.13, 1.35) | 4.74E-06 |
| ALM | 1.71 (1.14, 2.56) | 9.55E-03 | 3.69 (3.54, 3.85) | < 0.001 |
| WBFM | 1.05 (1.01, 1.1) | 0.026 | 2.63 (2.62, 2.65) | < 0.001 |
| FA | 0.92 (0.82, 1.03) | 0.169 | 1.07 (1.06, 1.08) | 3.97E-27 |
| Usual walking pace | 1.34 (1.14, 1.57) | 3.12E-04 | 0.93 (0.92, 0.95) | 9.34E-17 |
| Moderate to vigorous physical activity levels | 1.43 (1.00, 2.06) | 0.051 | 0.94 (0.91, 0.98) | 0.001 |
| DNA methylation GrimAge acceleration | 0.12 (0.01, 1.16) | 0.067 | 1.53 (1.21, 1.94) | 3.72E-04 |